Finally, one report described the utilization of a monoclonal AnxA1 antibody to suppress the autoimmune syndrome associated with an abnormal AnxA1 expression on activated B and T cells in a mouse model of systemic lupus erythematosus (SLE), thus underscoring the need for a balanced expression of this immune modulator [89]. This evidence concerns the gene ANXA1 and systemic lupus erythematosus.